Aim This study aimed to compare the effects of the molecular targeted drugs, sorafenib and
lenvatinib, on the survival, invasion, and angiogenesis of hepatocellular carcinoma cells …

ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Tumor cells express vascular endothelial growth factor (VEGF) that can activate VEGF
receptors (VEGFRs) on or within tumor cells to promote growth in an angiogenesis …

Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent
cancers worldwide, and current systemic therapeutic options for uHCC are limited …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Curative therapies for patients with hepatocellular carcinoma (HCC) are mainly invasive,
and with the exception of sorafenib, no medical treatments are available for advanced or …

The epithelial–mesenchymal transition (EMT) is considered an essential process for cancer
development and metastasis. Sorafenib, a RAF kinase and VEGFR-2 inhibitor, exhibits …

Purpose of study Hepatocellular carcinoma (HCC) is the third leading cause of cancer
death. Although sorafenib has been shown to improve survival of patients with advanced …

The evaluation of angiogenesis inhibitors requires the analysis of the precise structure and
function of tumor vessels. The anti-angiogenic agents lenvatinib and sorafenib are multi …

Angiogenesis and signaling through the RAS/RAF/mitogen-activated protein/extracellular
signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play …